- abnormal cell morphology / MGI
- abnormal crypts of Lieberkuhn morphology / MGI
- abnormal intestinal mucosa morphology / MGI
- increased body weight / MGI
- hyperglycemia / MGI
- neoplasm / MGI
- increased colonic adenoma incidence / MGI
- increased circulating insulin level / MGI
- hepatic steatosis / MGI
- increased liver weight / MGI
- large intestinal inflammation / MGI
- oxidative stress / MGI
- increased incidence of tumors by chemical induction / MGI
- impaired glucose tolerance / MGI
- insulin resistance / MGI
- increased susceptibility to weight gain / MGI
- increased susceptibility to diet-induced obesity / MGI
- abnormal mitochondrion morphology / MGI
- abnormal mitochondrial physiology / MGI
- abnormal epididymal fat pad morphology / MGI
- increased susceptibility to induced colitis / MGI
- abnormal renal fat pad morphology / MGI
- increased sensitivity to xenobiotic induced morbidity/mortality / MGI
- abnormal respiratory electron transport chain / MGI
- abnormal oxidative phosphorylation / MGI
- increased mitochondria number / MGI
- abnormal mitophagy / MGI
- increased body fat mass / MGI
- increased susceptibility to diet-induced non-insulin dependent diabetes / MGI
B6.Cg-Ptprca Trp53inp1tm1Acar/Orl
Status | Available to order |
EMMA ID | EM:06223 |
International strain name | B6.Cg-Ptprca Trp53inp1tm1Acar/Orl |
Alternative name | TP53INP1 KO Ly5.1 |
Strain type | Spontaneous |
Allele/Transgene symbol | Ptprca, |
Gene/Transgene symbol | Ptprc |
Information from provider
Provider | Alice Carrier |
Provider affiliation | Inserm U1068 / CRCM |
Genetic information | Null mutation of Trp53inp1 gene. |
Phenotypic information | Mouse model of chronic oxidative stress promoting cancer development. |
Breeding history | We already described the breeding history in our previous submissions of this KO mutation on C57BL/6 and 129/Sv background (EMMA strain ID EM:02038). For the present submission on Ly5.1 (Ptprca, or CD45 Ly5.1 allele), we have crossed homozygous KO on C57BL/6 (Ly5.2) background with wild-type Ly5.1 mice to obtain homozygous KO Ly5.1 in two steps. Those mice are mandatory to perform competitive bone-marrow reconstitution experiments. |
References |
|
Homozygous fertile | yes |
Homozygous viable | yes |
Homozygous matings required | no |
Immunocompromised | no |
Information from EMMA
Archiving centre | Institut de Transgenose, INTRAGENE, Orléans, France |
Animals used for archiving | homozygous C57BL/6J, homozygous C57BL/6J |
Breeding at archiving centre | To restore the right phenotype with the frozen sperm users should use C57BL/6-Ly5.1 (Ptprc-a) females for the IVF. Embryos have been obtained crossing males and females of the Trp53inp1-KO L5.1 (Ptprc-a) line so they all have the right genotype. |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- T-B+ severe combined immunodeficiency due to CD45 deficiency / Orphanet_169157
MGI phenotypes (allele matching)
Literature references
- Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1.;Gommeaux Julien, Cano Carla, Garcia Stéphane, Gironella Meritxell, Pietri Sylvia, Culcasi Marcel, Pébusque Marie-Josèphe, Malissen Bernard, Dusetti Nelson, Iovanna Juan, Carrier Alice, ;2007;Molecular and cellular biology;27;2215-28; 17242209
- Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.;Gironella Meritxell, Seux Mylène, Xie Min-Jue, Cano Carla, Tomasini Richard, Gommeaux Julien, Garcia Stephane, Nowak Jonathan, Yeung Man Lung, Jeang Kuan-Teh, Chaix Amandine, Fazli Ladan, Motoo Yoshiharu, Wang Qing, Rocchi Palma, Russo Antonio, Gleave Martin, Dagorn Jean-Charles, Iovanna Juan L, Carrier Alice, Pébusque Marie-Josèphe, Dusetti Nelson J, ;2007;Proceedings of the National Academy of Sciences of the United States of America;104;16170-5; 17911264
- Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function.;Cano Carla E, Gommeaux Julien, Pietri Sylvia, Culcasi Marcel, Garcia Stéphane, Seux Mylène, Barelier Sarah, Vasseur Sophie, Spoto Rose P, Pébusque Marie-Josèphe, Dusetti Nelson J, Iovanna Juan L, Carrier Alice, ;2009;Cancer research;69;219-26; 19118006
- Mutant mouse models of oxidative stress.;Pouyet Laurent, Carrier Alice, ;2010;Transgenic research;19;155-64; 19662508
- TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression.;Seux M, Peuget S, Montero M P, Siret C, Rigot V, Clerc P, Gigoux V, Pellegrino E, Pouyet L, N'Guessan P, Garcia S, Dufresne M, Iovanna J L, Carrier A, André F, Dusetti N J, ;2011;Oncogene;30;3049-61; 21339733
- Absence of tumor suppressor tumor protein 53-induced nuclear protein 1 (TP53INP1) sensitizes mouse thymocytes and embryonic fibroblasts to redox-driven apoptosis.;N'guessan Prudence, Pouyet Laurent, Gosset Gaëlle, Hamlaoui Sonia, Seillier Marion, Cano Carla E, Seux Mylène, Stocker Pierre, Culcasi Marcel, Iovanna Juan L, Dusetti Nelson J, Pietri Sylvia, Carrier Alice, ;2011;Antioxidants & redox signaling;15;1639-53; 21235351
- TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death.;Seillier M, Peuget S, Gayet O, Gauthier C, N'Guessan P, Monte M, Carrier A, Iovanna J L, Dusetti N J, ;2012;Cell death and differentiation;19;1525-35; 22421968
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).